Serum neurofilament light-chain levels and long-term treatment outcomes in relapsing-remitting multiple sclerosis patients: A post hoc analysis of the randomized CombiRx trial.

Gary R CutterRichard A RudickCarl de MoorCarol M SinghElizabeth FisherThijs KosterFred D LublinJerry S WolinskyHenry McFarlandSteven JacobsonMaria L Naylor

Published in: Multiple sclerosis journal - experimental, translational and clinical (2023)

sNfL levels were reduced within 6 months and remained low at 36 months. Results suggest that the combination of lesion activity and sNfL was a stronger predictor of relapse than either factor alone.

Keyphrases

multiple sclerosis
end stage renal disease
phase iii
white matter
phase ii
ejection fraction
clinical trial
newly diagnosed
double blind
chronic kidney disease
placebo controlled
prognostic factors
study protocol
peritoneal dialysis
patient reported outcomes